Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.48 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6830704 | 0.94 | CNR2 (0.50) | CNR2TAS2R14TP53POLBALDH1A1 | |
| SCHEMBL6806990 | 0.84 | PKM (0.52) | CNR2TAS2R14MAPTALDH1A1LMNA | |
| SCHEMBL6800802 | 0.83 | ALDH1A1 (0.47) | CNR2TAS2R14TP53MAPTPTPN1 | |
| SCHEMBL7067656 | 0.81 | STAT5B (0.44) | CNR2TAS2R14TP53PTPN1POLB | |
| SCHEMBL6803486 | 0.79 | TP53 (0.47) | CNR2TAS2R14TP53POLBALDH1A1 | |
| SCHEMBL6803488 | 0.78 | LIMK2 (0.49) | CNR2TAS2R14TP53MAPTPOLB | |
| SCHEMBL6803887 | 0.77 | CNR2 (0.56) | CNR2TAS2R14TP53ALDH1A1 | |
| SCHEMBL10463396 | 0.75 | MEN1 (0.52) | CNR2TAS2R14TP53MAPTPOLB | |
| SCHEMBL7014542 | 0.74 | CNR2 (0.68) | CNR2TAS2R14TP53POLBALDH1A1 | |
| SCHEMBL6807719 | 0.72 | CNR2 (0.51) | CNR2TAS2R14TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004074238-A1 | PHENETHYLAMINO SULFAMIC ACIDS | THE PROCTER & GAMBLE COMPANY (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040167183-A1 | Phenethylamino sulfamic acids | THE PROCTER & GAMBLE COMPANY | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167183-A1 | Phenethylamino sulfamic acids | PTPRM, PTPRS, PTPRE | CNR2 4684/4885TAS2R14 3019/4885TP53 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.